11-18-05



NOV 1 7 2005

7 2005				U.	.S. Patent and	Trademark Office;	PTO/SB/21 (09-04) e through 07/31/2006. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE
AARK SOnder the Page	rwork Re	duction Act of 1995	no persons	s are required to respond to a Application Number	collection of 1		t displays a valid OMB control number.
TRA	NSI	MITTAL		Filing Date	<u> </u>	23, 2003	
	FOI			First Named Inventor	Bradley,		
	1 01	ZIVI		Art Unit	1654		
l.				Examiner Name	Unassign		
(to be used for all	l correspo	ndence after initial	filing)	Attorney Docket Number	<u>. </u>		
Total Number of P	Pages in T	his Submission	15	Attorney Docket Number	B185 T1	015.1	
			ENCL	LOSURES (Check	all that app		Allowance Communication to TC
Amendmen Afte Affic Extension of	Attache at/Reply er Final davits/de	eclaration(s)		Orawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revoca Change of Correspondence Ferminal Disclaimer Request for Refund		Appe (Appe Propi	torney to Prosecute Applications
Information Disclosure Statement CD, Number of				CD, Number of CD(s) Landscape Table on	CD	Statement	under 37 CFR 3.73(b); ecuted Assignment
		SIGNA	TURE O	F APPLICANT, ATT	TORNEY,	OR AGENT	
Firm Name	Vomble	Carlyle Sandridge	e & Rice, F	PLLC			
Signature		m	m	nru			
Printed name	Carl B. M	lassey, Jr.					
Date	Date 10.16,205 Reg. No. 44,224						
	this con	CI respondence is b	ERTIFIC	CATE OF TRANSMIS	PTO or depo	osited with the U	nited States Postal Service with Alexandria, VA 22313-1450 on
Signature					<u>-</u>		
Typed or printed na	ıme					Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/80 (04-05)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

NOV 1 7 2005

A TRADEM

	I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).						
	/ appoint:			.			
X Pra	actitioners associa	ated with the Customer Number:	26158				
OR			<u> </u>				
Pra	actitioner(s) name	d below (if more than ten patent p	practitioners are to b	e named, then a custor	mer number must be us	ed):	
	-	Name	Registration Number	Na	me	Registration	
			Number	· · · · · · · · · · · · · · · · · · ·		Number	
				 		 	
\vdash							
<u> </u>				·		ļ	
<u> </u>					······	ļ	
ــ ــ ــــــــــــــــــــــــــــــــ						<u> </u>	
any and a	ili patent applicati	o represent the undersigned befo ons assigned <u>only</u> to the undersig ordance with 37 CFR 3.73(b).					
Please ch	ange the corresp	ondence address for the applicat	ion identified in the a	attached statement und	ler 37 CFR 3.73(b) to:		
					7		
X	The address ass	ociated with Customer Number:	26158				
OR					j		
	m or dividual Name						
Address							
City			State		Zip		
Country							
Telepho	ne			Email			
L							
_	Name and Addre						
		erapeutics, Inc.					
	4101 Research Commons, 79 T.W. Alexander Drive						
Research Triangle Park, NC 27709							
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be							
filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of							
the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee,							
and must identify the application in which this Power of Attorney is to be filed.							
SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignee							
Signature		1/1/4		C	Date Nivember 7	2005	
Name	Randal1	1 A. Jones Telephone 919.316.6474					
Title							
			00 T) 1.6 W				

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

NOV 1 7 2005

Under Are Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRADEM	AFRE	STATEMENT UNDE	K 3 / CFK 3. /3(D)	
Applica	nt/Patent Owner: Bradley, et al.			<u> </u>
Applica	tion No./Patent No.: 10/692,105 File	ed/Issue Date:	October 23, 2003	
Entitled	: PROCESS FOR THE PRODUCTI	ON OF A REVERSIBLY	Y INACTIVE ACIDIFIED	PLASMIN COMPOSITION
	Biotherapeutics, Inc. Assignee)	, a <u>corporation</u> (Type of Assign	nee, e.g., corporation, partnership	o, university, government agency, etc.)
states th	at it is: the assignee of the entire right, title,	and interest; or		
2. 🗌	an assignee of less than the entire ri The extent (by percentage) of its ow		%	
in the pa	atent application/patent identified abo	ove by virtue of either:		
A. 🛛	An assignment from the inventor(s) United States Patent and Trademark attached.	of the patent application COffice at Reel	n/patent identified above, Frame	The assignment was recorded in the, or for which a copy thereof is
OR B. \square	A chain of title from the inventor(below:	s), of the patent applicat	tion/patent identified abov	ve, to the current assignee as shown
	1. From: The document was recorde Reel, Fra	d in the United States Pa	tent and Trademark Office	at
	2. From:		To:	
	The document was recorde	d in the United States Pa	tent and Trademark Office	
	Reel , Fra	ime	, or for which a copy the	ereof is attached.
	3. From:		То:	
	The document was recorde	d in the United States Pa	tent and Trademark Office	e at
			, or for which a copy the	
	Additional documents in the ch	ain of title are listed on a	supplemental sheet.	
	ies of assignments or other document OTE: A separate copy (i.e., a true cop accordance with 37 CFR Part 3, if the	y of the original assignm	ent document(s)) must be	submitted to Assignment Division in USPTO. See MPEP 302.08]
The und	ersigned (whose title is supplied belo	ow) is authorized to act or	n behalf of the assignee.	
	mym	~~~~		lov. 16, 2005
	Signatu			Date
	Carl B. Massey, Jr. (I			336.721.3681
	Printed or Typ			Telephone Number
	Attorney of Title		 	
	THE			

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT ASSIGNMENT

This PATENT ASSIGNMENT ("Assignment") dated as of March 31, 2005 (the "Effective Date"), is by and between Bayer HealthCare LLC, a Delaware limited liability company with an office at 400 Morgan Lane, West Haven, CT 06516 ("Bayer" or "Assignor") and Talecris Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.), a Delaware corporation with an office at 79 TW Alexander Drive, 4101 Research Commons, Research Triangle Park, Raleigh, NC 27709 ("Assignee").

In the Amended and Restated Joint Contribution Agreement dated as of March 30, 2005, by and among Bayer, Talecris Holdings, LLC (f/k/a NPS Bio Holdings, LLC), a limited liability company organized under the laws of the state of Delaware, Talecris Biotherapeutics Holdings Corp., a corporation organized under the laws of the state of Delaware, and Assignee (the "Contribution Agreement"), Bayer has agreed to transfer or to cause one or more of its Affiliates to transfer to Assignee, certain assets, specified in the Contribution Agreement by execution of certain agreements including, without limitation, one or more Assignment and Assumption Agreements contemplated to be executed concurrently herewith, and one or more transfer documents. This Assignment is a transfer document in accordance with the Contribution Agreement and the assets transferred hereby may also be subjects of one or more of such Assignment and Assumption Agreements. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Contribution Agreement.

In consideration of the representations, warranties, covenants and agreements in the Contribution Agreement, the parties agree as follows:

1. Assignment

Assignor hereby contributes, assigns and transfers to Assignee, and Assignee hereby accepts the contribution, assignment and transfer from Assignor of, all of its right, title and interest in and to the issued patents and pending patent applications listed in the attached Schedule 1A (collectively, the "Patents") together with any extension, reissue, modification or renewal thereof, and (i) all rights, Claims, credits or rights of set-off against third persons for infringement or other violation of the Patents arising on or after the Effective Date or as otherwise provided in the Contribution Agreement, whether liquidated or unliquidated, fixed or contingent including any claim, demand, suit, inquiry, investigation, proceeding, action (including any governmental action) or cause of action of any kind or character (in each case, whether civil, criminal, investigative or administrative), seeking monetary damages, fines, penalties, recall required by Governmental Authority, seizures, detentions, injunctions, or any equitable or other relief or sanction under any theory, including those based on theories of contract, tort, equity, statutory liability against third persons for infringement or other violations of the Patents, and (ii) all income, royalties or payments exclusively relating to the Patents due or



This PATENT ASSIGNMENT ("Assignment") dated as of March 31, 2005 (the "Effective Date"), is by and between Bayer HealthCare LLC, a Delaware limited liability company with an office at 400 Morgan Lane, West Haven, CT 06516 ("Bayer" or "Assignor") and Talecris Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.), a Delaware corporation with an office at 79 TW Alexander Drive, 4101 Research Commons, Research Triangle Park, Raleigh, NC 27709 ("Assignee").

In the Amended and Restated Joint Contribution Agreement dated as of March 30, 2005, by and among Bayer, Talecris Holdings, LLC (f/k/a NPS Bio Holdings, LLC), a limited liability company organized under the laws of the state of Delaware, Talecris Biotherapeutics Holdings Corp., a corporation organized under the laws of the state of Delaware, and Assignee (the "Contribution Agreement"), Bayer has agreed to transfer or to cause one or more of its Affiliates to transfer to Assignee, certain assets, specified in the Contribution Agreement by execution of certain agreements including, without limitation, one or more Assignment and Assumption Agreements contemplated to be executed concurrently herewith, and one or more transfer documents. This Assignment is a transfer document in accordance with the Contribution Agreement and the assets transferred hereby may also be subjects of one or more of such Assignment and Assumption Agreements. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Contribution Agreement.

In consideration of the representations, warranties, covenants and agreements in the Contribution Agreement, the parties agree as follows:

1. Assignment

Assignor hereby contributes, assigns and transfers to Assignee, and Assignee hereby accepts the contribution, assignment and transfer from Assignor of, all of its right, title and interest in and to the issued patents and pending patent applications listed in the attached Schedule 1A (collectively, the "Patents") together with any extension, reissue, modification or renewal thereof, and (i) all rights, Claims, credits or rights of set-off against third persons for infringement or other violation of the Patents arising on or after the Effective Date or as otherwise provided in the Contribution Agreement, whether liquidated or unliquidated, fixed or contingent including any claim, demand, suit, inquiry, investigation, proceeding, action (including any governmental action) or cause of action of any kind or character (in each case, whether civil, criminal, investigative or administrative), seeking monetary damages, fines, penalties, recall required by Governmental Authority, seizures, detentions, injunctions, or any equitable or other relief or sanction under any theory, including those based on theories of contract, tort, equity, statutory liability against third persons for infringement or other violations of the Patents, and (ii) all income, royalties or payments exclusively relating to the Patents due or

payable for any period on or after the Effective Date under any Contract (all collectively, the "Patent Rights").

Assignor shall provide to Assignee cooperation and assistance at Assignee's reasonable request (including, without limitation, the execution and delivery of any affidavits, declarations, oaths, samples, exhibits, specimens and other documentation as may be reasonably required): (1) in the preparation and prosecution of any application for the Patent Rights; (2) in the prosecution or defense of any interference, infringement or other proceedings that may arise in connection with any of the Patent Rights, including, without limitation, testifying as to any facts relating to the Patent Rights assigned herein and this Assignment; and (3) in the implementation or perfection of this Assignment; provided that Assignee shall be responsible as to (1) - (3) above for the reasonable direct costs of Assignor which includes (i) employee costs (including, for example, salaries, benefits, relocation, travel, and training and development) and employee supporting costs (including, for example, computer and software, telephone usage, supplies, and depreciation of office equipment and furnishings) for employees working directly on (1) - (3) above, pro rated for the amount of time spent by such employees working directly on (1) - (3) above, but in no event shall this include any general overhead costs (including, for example, depreciation for office building space, information technology infrastructure, site maintenance, medical department, cafeteria, security, communications, safety, heating and cooling, water and sewage, electricity, gas, and general administration), and (ii) documented out-of-pocket costs incurred in the provision of (1) - (3) above, including, without limitation, attorney fees for counsel for Assignor selected at the sole discretion of Assignor.

2. Parties' Rights and Remedies

The rights and remedies of each party under the Contribution Agreement shall not be deemed to be enlarged, modified or altered in any way by this Agreement. This Assignment is made without representation or warranty except as provided in and by the Contribution Agreement.

3. Governing Law

This Assignment shall be governed by and construed in accordance with the laws of the State of New York without giving effect to the principles of conflicts of law thereof.

4. Counterparts

This Assignment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument.

payable for any period on or after the Effective Date under any Contract (all collectively, the "Patent Rights").

FRA

Assignor shall provide to Assignee cooperation and assistance at Assignee's reasonable request (including, without limitation, the execution and delivery of any affidavits, declarations, oaths, samples, exhibits, specimens and other documentation as may be reasonably required): (1) in the preparation and prosecution of any application for the Patent Rights; (2) in the prosecution or defense of any interference, infringement or other proceedings that may arise in connection with any of the Patent Rights, including, without limitation, testifying as to any facts relating to the Patent Rights assigned herein and this Assignment; and (3) in the implementation or perfection of this Assignment; provided that Assignee shall be responsible as to (1) - (3) above for the reasonable direct costs of Assignor which includes (i) employee costs (including, for example, salaries, benefits, relocation, travel, and training and development) and employee supporting costs (including, for example, computer and software, telephone usage, supplies, and depreciation of office equipment and furnishings) for employees working directly on (1) - (3) above, pro rated for the amount of time spent by such employees working directly on (1) - (3) above, but in no event shall this include any general overhead costs (including, for example, depreciation for office building space, information technology infrastructure, site maintenance, medical department, cafeteria, security, communications, safety, heating and cooling, water and sewage, electricity, gas, and general administration), and (ii) documented out-of-pocket costs incurred in the provision of (1) - (3) above, including, without limitation, attorney fees for counsel for Assignor selected at the sole discretion of Assignor.

2. Parties' Rights and Remedies

The rights and remedies of each party under the Contribution Agreement shall not be deemed to be enlarged, modified or altered in any way by this Agreement. This Assignment is made without representation or warranty except as provided in and by the Contribution Agreement.

3. Governing Law

This Assignment shall be governed by and construed in accordance with the laws of the State of New York without giving effect to the principles of conflicts of law thereof.

4. Counterparts

This Assignment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument.



[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, Assignor and Assignee each has caused this instrument to be executed by its respective duly authorized representative as of the Effective Date.

BAYER	JEA]	LTHC	ARE	LL	C

By

Name: Title:

Executive Vice President

BAYER HEALTHCARE LLC

Ву

Name:

Keith Abrams

Title:

Assistant Secretary

TALECRIS BIOTHERAPEUTICS, INC.

Name: Title:

Lawrence Stern

Executive Chairman,

President and Chief Executive Officer

CERTIFICATE OF ACKNOWLEDGMENT

CITY OF WASHINGTON	
SS.:	
DISTRICT OF COLUMBIA	
On this 31st day of March Joseph AKers, to me k foregoing instrument, and who, being duly swo Executive Via President of Baye liability company, and that he executed the f Bayer HealthCare LLC, and that he had author to me that he executed the same as the act and otherein mentioned.	rn by me, did depose and say that he is the r HealthCare LLC, a Delaware limited foregoing instrument in the firm name of ity to sign the same, and he acknowledged deed of said firm for the uses and purposes
	Notary Public – District of Columbia
	Printed Name Linda C. Brown
My Commission Expires: LINDA C. BROWN NOTARY PUBLIC OF DISTRICT OF COLUMBIA My Commission Expires August 31, 2006	

CERTIFICATE OF ACKNOWLEDGMENT

CITY OF WASHINGTON
ss.:
DISTRICT OF COLUMBIA
On this 31 st day of Mach 2005, before me personally came Korth florams, to me known to be the person who executed the foregoing instrument, and who, being duly sworn by me, did depose and say that he is the Assistant Secretary of Bayer HealthCare LLC, a Delaware limited liability company, and that he executed the foregoing instrument in the firm name of Bayer HealthCare LLC, and that he had authority to sign the same, and he acknowledged to me that he executed the same as the act and deed of said firm for the uses and purposes
therein mentioned.
Missa C. Sw
Notary Public - District of Columbia
Printed Name Linda C. Brown
My Commission Expires: LINDA C. BROWN NOTARY PUBLIC OF DISTRICT OF COLUMBIA My Commission Expires August 31, 2008

Schedule 1A: Patents and Patent Applications

Schedule 1A

Assignes			Bayer HealthCare LLC	
	• • • • • • • • • • • • • • • • • • •	; ; <u></u>	Expires 11/13/19	
Issue Dete			03/12/02	
Patent No.			6,355,243	
Filling Dete			11/13/99	_
Application Sental No.	•	:	09/438,331	
Coelenany Coele	· ·		Sn	•
Trade Nerme/Product				
T N			nbolysis y of Active n Process	
e M_			Method of Thrombolysis by Local Delivery of Active Plasmin, Plasmin Formulation and Process of Producing	

Schedule 1A

- 157 A.				
Assignae	Bayer HealthCare LLC	_	<u>-</u> -	
Status	Pending			
Issue Date	e.		_	
टाइमा No				
Almo Date P	05/10/02			10/23/2003
Napillestition	10/143,156			10/692,105
Countiny A	US	-	· ·	US 1
Trizide Nemie/Product				
	Reversibly ed Plasmin			Reversibly d Plasmin
Title	Process for the Production of a Reversibly Inactive Acidified Plasmin Composition			Process for the Production of a Reversibly Inactive Acidified Plasmin Composition

EXPRESS MAIL CERTIFICATE

Express Mail" mailing label number

EL 983 779 317 US

Date of Deposit

November 17, 2005

Type of Documents

Transmittal Form (1 page);

Power of Attorney to Prosecute Applications

Before the USPTO (1 page);

Statement under 37 CFR 3.73(b) (1 page);

Copy of executed Assignment (12 pages); and

(signature)

Return Postcard

Application No.

10/692,105

Filed

October 23, 2003

I hereby certify that the documents identified above are being deposited with the United States

Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date

indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

Heather Norman

WINSTON 1627253v1